1. HIMS & Hers Reports Largest Single-Day Share Collapse in Three Months as Strategic Shift to Branded GLP-1 Drugs Triggers Revenue Miss and Restructuring Charges
HIMS & Hers Health, the direct-to-consumer telehealth platform, experienced its steepest single-session stock decline in three months after reporting first-quarter results that fell short of Wall Street expectations, signaling growing pressure on the company's transition strategy away from compounded GLP-1 weight-loss ...